# Lost Opportunity in Tobacco Cessation Care: Impact of Underbilling in a Large Health System

- 4
- 5 Derek J Baughman, MD<sup>1</sup>; Marcus Rauhut, MPS<sup>2</sup>; Edward Anselm, MD<sup>3</sup>

-		
6 7	1.	Telemedicine Physician, WellSpan Health   Dept. Biomedical Informatics, Vanderbilt University baughman.derek@gmail.com
8	2.	Senior Specialist - Research & Development, WellSpan Health
9		mrauhut@wellspan.org
10	3.	Assistant Clinical Professor of Medicine, Icahn School of Medicine at Mount Sinai
11		eanselm@msn.com
12		
13		
14		
15	Manus	script Word count: <b>2899</b>
16		act Word count: 238
17	Tables	
18	Tables	э. т
19	MeSH	: Tobacco, Health Care Economics and Organizations, Primary Health Care, Clinical
20		g, Public Health
20	Coum	g, i done riediti
22	A 11 au	thors have contributed significantly to the work, meet ICMJE criteria, and approve the
22		
		cript for submission. There are no conflicts of interest to disclose, financial or otherwise,
24		I study procedures were conducted under ethical standards. No funding was received for
25	this stu	udy.

2	6
4	U

# Abstract

27	Introduction: Tobacco cessation remains a critical challenge in healthcare, with evidence-based
28	interventions often under-utilized due to misaligned economic incentives and inadequate
29	training. This study aims to quantify the economic impact of missed billing opportunities for
30	tobacco cessation in a healthcare system, thereby assessing potential revenue loss and evaluating
31	the effectiveness of systems-based approaches in enhancing tobacco cessation efforts.
32	Methods: A retrospective cohort study utilized aggregated de-identified patient health data from
33	an 8-hospital regional health system across Pennsylvania and Maryland, from 1/1/21 to 12/31/23.
34	The analysis focused on primary care encounters eligible for tobacco cessation counseling (CPT
35	codes 99406 or 99407), with potential revenue calculated based on the Medicare reimbursement
36	rate.
37	Results: Over three years, and 507,656 office visits, only 1,557 (0.3%) of encounters with
38	persons using tobacco were billed for cessation services. The estimated total potential revenue
39	gained if each person who was identified as using tobacco was billed consistently for tobacco
40	cessation counseling was \$5,947,018.13, and \$1,982,339.38 annually.
41	
42	Conclusions: The study reveals a significant gap between the potential and actual billing for
43	tobacco cessation services, highlighting not only the financial implications of missed
44	opportunities but the validation of health system's public health impact. Underbilling contributes
45	to considerable annual revenue loss and undermines primary prevention efforts against tobacco-
46	related diseases. Our findings illuminate the need for enhanced billing practices and systemic
47	changes, including policy improvements that influence proper billing to promote public health
48	benefits through improved tobacco cessation interventions.

49

## Introduction

50 Despite the progress in reducing the prevalence of adult smoking in the United States, which is 51 now at 11.5%, there are still over 28.3 million adult persons using cigarettes who could benefit from quitting.<sup>1</sup> The US prevalence of all forms of tobacco use combined is estimated at 18.7%.<sup>1</sup> 52 According to the recent Surgeon General's Report on Smoking Cessation (2020).<sup>2</sup> 77% of people 53 54 who smoke express interest in quitting, with 55.4% of persons who smoke making a quit attempt 55 in the previous year. Unfortunately, fewer than one-third of persons using cigarettes attempting 56 to quit utilize evidence-based interventions like FDA-approved cessation medications or behavioral counseling.<sup>3</sup> This shortfall in the use of interventions contributes to higher relapse 57 58 rates, with successful quitters often needing up to 20 attempts in the absence of counseling and 59 medications.<sup>2</sup> Surveys show that from the patient's perspective, physicians are advising patients 60 to guit smoking routinely but not directing them to evidence-based treatment. Each year, the 61 National Committee for Quality Assurance (NCQA) surveys members of every health plan to explore a variety of customer satisfaction measures.<sup>4</sup> NCQA surveys for 2021 reveal that 44% of 62 63 Commercial HMO members don't receive counseling on how to quit, and fewer than 40% of 64 patients have discussions about medications. These national survey data, repeated yearly, show 65 that even when clinicians provide advice to quit, that intervention is often incomplete, lacking 66 discussion of medication and cessation strategies. NCQA data may have significant response 67 bias, which may lead to under-reporting of prevalence and overstatement of cessation interventions.<sup>5</sup> Another perspective on tobacco cessation interventions comes from the National 68 69 Health Interview Surveys, which stated that 63% of smokers reported physician advice to quit, and 6.2% were given a prescription in the most recent year sampled.<sup>6</sup> 70

71

72 Sadagna, et. Al. reported that in a large contemporary US registry, only 1 in 3 persons using 73 cigarettes presenting for cardiology visits received smoking cessation assistance.<sup>7</sup> Further, 74 several reports looking at administrative data reveal significant variation and overall underperformance in the provision of smoking cessation services,<sup>8,9,10</sup> which were attributed to 75 76 barriers like time constraints, lack of training, and low reimbursement. In a Medicaid claims 77 analysis across 37 states (where an average of 9.4% of people who smoke attempted to quit 78 within the last year), cessation medication claims ranged from 0.2% to 32.9%, and an average of only 2.7% received cessation counseling (ranging from 0.1% to 5.6%).<sup>10</sup> The majority of studies 79 80 on tobacco cessation are focused specifically on smoking of cigarettes, but that literature can be 81 applied to tobacco overall. The billing and coding of services for all forms of tobacco use are the same, Error! Bookmark not defined.<sup>21</sup> and the FDA-approved medications containing nicotine 82 83 can be used interchangeably for any treatment of nicotine dependence, and non-nicotine medications appear to be effective as well.<sup>11</sup> 84

85

Advising a tobacco user to quit is a standard of care<sup>12</sup> which is not usually captured in 86 87 administrative data. Counseling persons using tobacco for three minutes or ten minutes is a 88 billable service. Clinical practice guidelines support the delivery of a billable, evidence-based intervention at every clinical encounter, regardless of a patient's readiness to change.<sup>13</sup> Much of 89 what is known about clinical performance in tobacco cessation is gleaned from survey data.<sup>14</sup> 90 91 Medical claims systems and EMR systems are likely to significantly under-report tobacco use status.<sup>15,16</sup> Aside from the known challenges with electronic medical records-based claims and 92 reimbursement,<sup>17</sup> the potential revenue lost due to ineffective billing and underlying poor service 93 94 delivery for cessation services remains largely unexplored. The lost revenue can be a marker for

95 indicating sub-optimal interventions in health systems and quantifying the economic impact of
96 missed tobacco cessation care.

97

- 98 This study aims to evaluate the potential revenue lost in tobacco cessation care due to inadequate
- 99 billing practices. Inadequate billing reflects a mix of services not provided and services
- 100 provided but not billed. By using lost revenue as a proxy, the study intends to measure the
- 101 potential impact of applying systems-based approaches in population health for tobacco
- 102 cessation. The objective is to develop an analysis framework for researching clinical data from
- 103 multiple EMRs, increasing awareness in billing practices, and ultimately enhancing the
- 104 effectiveness of tobacco cessation interventions.

106	Methods
107	Study Sample
108	
109	In this cohort study, we used aggregated de-identified, patient-level health data to make
110	population-level estimates of persons using tobacco across an 8-hospital health system,
111	WellSpan Health. De-identified data from over 200 outpatient care locations across Pennsylvania
112	and Maryland were mined to reveal the total number of primary care encounters eligible for
113	tobacco cessation counseling. Over a three-year period, we examined patient's tobacco use and
114	whether tobacco cessation counseling was billed (CPT codes 99406 or 99407). Inclusion criteria
115	are summarized in Table 1.
116	
117	Tobacco use status in electronic medical records will reflect the inconsistencies of the practices
118	that collect this data. <sup>16</sup> Despite best practices to screen for tobacco use at every visit and update
119	the medical record accordingly, <sup>18</sup> we recognized that many practices do not routinely capture
120	tobacco use and may miss some tobacco users, and recent quitters might continue to be listed as
121	current users.
122	
123	Measures
124	For data mining and inclusion criteria, we used custom data sessions within Epic's SlicerDicer to
125	model similar data capture and analysis across varying Electronic Medical Record (EMR)
126	systems. Primary population filters in Epic's SlicerDicer were used to obtain comprehensive
127	patient-level and visit-level data. The timeframe was three years between January 1, 2021, and
128	December 31, 2023. Persons using tobacco were identified using standard ICD-10 coding based

129	on CMS standards. Error! Bookmark not defined.21 Adults aged 18 and over were identified through
130	structured data elements in the EMR indicating tobacco use status (Table 1). Patients in hospice
131	care were excluded as CMS does not pay for tobacco cessation for this population. This
132	identification was derived from medical history records, active problem lists, or specific tobacco
133	cessation billing codes. We used groupers to include sub-codes and decimal versions of ICD-10
134	codes for nicotine dependence (F17.*), tobacco use (Z72.0), and tobacco abuse (Z71.6); these
135	details are in the appendix.
136	
137	Regarding visit types, outpatient and telemedicine visits in the primary care service line were
138	used exclusively, and data was reported in terms of unique patients and individual visits to
139	provide context to the patient-to-visit ratio. Inpatient encounters, emergency department visits,
140	and any visits by hospice patients were excluded.
141	
142	To assess the prevalence of tobacco use in our patient cohort, was calculated by dividing the
143	number of identified persons using tobacco by the total population. This calculated prevalence
144	was then compared to the state health department's tobacco use prevalence rates to ensure
145	reliability. <sup>19</sup>
146	
147	To determine and compute the billing rate, we examined the subset of the tobacco-using
148	population billed for CPT codes 99406 or 99407 during the specified study period. Patients
149	billed once or more (but less than eight) sessions per year proxied the frequency of cessation
150	counseling. This data was segmented to differentiate between telemedicine (including audio-
151	only) versus office encounters. To compare the revenue loss per patient and per visit, we

152 calculated both billing rates by dividing the number of patients or visits billed for CPT codes
153 99406 or 99407 by the total number of identified tobacco users (i.e., patients) or their total
154 number of encounters (i.e., visits).

155

156 To estimate the unrealized potential revenue loss, we identified persons using tobacco who were 157 not billed for CPT codes 99406 or 99407. The reimbursement was calculated based on insurance 158 type. Medicare reimburses up to eight cessation attempts within a 12-month period, with private plans and Medicaid typically adhering to these guidelines.<sup>20</sup> Visits that were ineligible for 159 160 reimbursement due to exceeding this limit or because of the patient's hospice status were 161 excluded from our analysis. The resulting number was then multiplied by the payer-specified 162 reimbursement rate to estimate the financial impact of underbilling for tobacco cessation 163 counseling services. The standard Medicare reimbursement rate for the three-minute counseling 164 visit, 99406, was used for the calculation. The base rate of \$14.97 was multiplied by 1.4 for commercial insurance and reduced by 70% for Medicaid.<sup>21</sup> Since the majority of billable visits 165 166 were for patients with Medicare, Medicaid, and commercial insurance types, these were reported. 167 Other types of insurance and uninsured patients were removed from the estimates of missed 168 opportunities.

169

Regarding demographics, data on five variables from patients 18 years and older who had an
office visit or video visit at a primary care office between January 1, 2021, and December 31,
2023, was reported. The data for race and ethnicity were aggregated based on standards set by
the U.S. Department of Health and Human Services and Office of Management and Budget.<sup>22</sup>
The sex of the patient was based on the legal sex documented in the patient's chart. Age

175	categories were based on the patient's age at the time of the visit. Insurance data was based on
176	the primary payer who covered the visit. Cumulative percentages of age group and insurance
177	type exceeded 100% because patients may have had multiple encounters at different ages or with
178	different insurance coverage during the study period. After building demographic criteria, we
179	then grouped patients into segments based on whether they had an office visit or video visit.
180	Cumulative percentages for visit type exceed 100% because patients may have visits using both
181	modalities during the study period.
182	
183	The WellSpan Health Institutional Review Board (IRB) waived full ethical review, categorizing
184	the study as "non-human subjects research" (IRB: HE-2023-101) according to the regulations
185	established by the DHHS and the FDA under 45 CFR 46.102 and 21 CFR 50.3, respectively.
186	
187	Results
188	A total of 584,631 unique patients who met the study inclusion criteria during the three-year
189	sample period were identified. Demographics (Table 2) revealed a predominately white (83.4%)
190	and non-Hispanic or Latino (88%) population. Over half (55.5%) were covered by commercial
191	insurance, while Medicare accounted for 26.5% of patients and Medicaid 15.8%. There was a
192	slightly higher representation of females (54.6%). Patients were distributed among four age
193	groups, with the majority being older adults (22.1% aged 18-29 years, 26.2% aged 30-44 years,
194	34.4% aged 45-64 years, and 26.9% aged 65 years and above). The primary visit modality was
195	
	in-office (91.1% of patients had at least one office visit), while 13.6% of patients had at least one
196	video visit (4.6% had both).

198 A total of 75,115 persons using tobacco were identified over the study timeframe, or 12.8% of 199 the patient population (Table 3). This was comparable to the state-specific figures on tobacco use recorded at 14.4% for Maryland and 18.5% for Pennsylvania.<sup>23</sup> These patients had 507,656 total 200 201 primary care encounters over the timeframe potentially eligible for receiving tobacco cessation 202 counseling. We found only 1,277 patients, or 1.7% of eligible patients, were billed for tobacco 203 cessation counseling during the study period. 204 205 In terms of encounters, tobacco users had 507,656 office visits (Table 2), and only 1,557 (0.3%) 206 were billed for cessation services. Over the 3-year timeframe, patients with Medicare, Medicaid, 207 and commercial insurance had a total of 402,498 potentially eligible visits that were not billed for tobacco cessation counseling (Table 4). Of the eligible opportunities to provide and bill for 208 209 tobacco cessation services, 97% appear to have been missed. The estimated potential

reimbursement for tobacco cessation care, if provided and billed consistently, was \$5,947,018.13

211 over three years (Table 4).

212

# Discussion

213 This study found a significant gap between persons using tobacco and billed encounters for 214 tobacco cessation care. Leveraging a large health system's aggregated patient data, the 215 unrealized revenue highlights two concerns in tobacco cessation care: underbilling (when 216 billable care may have been rendered), and failure to provide care to eligible patients. The 217 findings highlight the importance of improving billing practices, even in telemedicine, which has 218 become increasingly common and can represent a significant proportion of the population 219 (13.6% of our study's participants, as shown in Table 2). Given the prevalence of tobacco use, 220 the impact of missed opportunities to help patients quit the use of tobacco is profound.

221

222	Our reported billing rate—1.7 % overall, is consistent with other studies. <sup>10</sup> In a recent study of an
223	EMR-enabled smoking treatment program, the pre-intervention baseline was 2.1%. <sup>24</sup> But survey
224	data supports persons using cigarettes' affirmation that their doctors are providing tobacco
225	cessation services at a much higher rate. <sup>25,14</sup> This highlights the importance of improving billing
226	practices, even in telemedicine, which has become increasingly common and can represent a
227	significant proportion of the population (13.6% of our study's participants, as shown in Table 2).
228	The billing rates for relevant CPT codes (99406 or 99407) were considerably low, despite the
229	significant portion of the eligible population that could benefit from cessation interventions, <sup>26</sup> as
230	indicated by the overall visit-level billing rate of only 0.3% (Table 3).
231	
232	It is important to note in our analysis that eligibility for tobacco cessation services was not static.
233	This reflects the reality that patients' smoking status changes over time, impacting their potential
234	eligibility for cessation services within the study timeframe. Methodologically, if the EHR
235	indicated the patient had quit, they would no longer trigger eligibility for cessation interventions
236	in subsequent visits. However, our use of aggregate data does not allow for distinguishing
237	between patients moving in and out of the health system from patients who drop off the
238	eligibility threshold. Nonetheless, the billing rate remained consistently low at around 0.3%
239	(Table 3) despite patient and visit numbers changing over the study timeframe. Additionally, by
240	excluding uninsured and other unmeasured insurance from our calculations, over the three years,
241	the potential revenue lost is still estimated at \$5,947,018.13, demonstrating a substantial financial
242	impact. This translates to an average \$1,982,339.38 potential revenue loss per year. Moreover,

this is potential revenue that is not reinvested into frontline clinicians and their patients—

blunting the impact of primary prevention.

245

Many studies explore the barriers to systemic implementation of tobacco cessation in detail.<sup>27,28</sup> 246 247 however, there is a notable gap in the literature concerning the reimbursement perspective. The 248 most frequently reported perceived barriers to providing cessation services were time constraints, 249 high workload, lack of training, lack of reimbursement of smoking cessation interventions, and the physician's own smoking status. Error! Bookmark not defined. Low outcome expectancy, lack of self-250 251 efficacy, fear of losing patients, being uncomfortable discussing smoking hazards, and dissatisfaction with professional activity were also reported. Error! Bookmark not defined.,29 Other 252 253 studies have produced similar results in assessing effective smoking cessation intervention in primary care<sup>30</sup> and tobacco treatment guideline use and predictors among U.S. physicians by 254 specialty.<sup>31</sup> 255

256

257 Our study's results call for a strategic healthcare policy review by every system, tracking the 258 prevention and screening opportunity from encounter to outcome and reimbursement. In seeking 259 to optimize systems performance in identifying persons using tobacco, accurate documentation 260 of a visit, shaping additional treatment and follow-up, and capturing appropriate billing, AIdriven clinical billing systems have a clear potential role.<sup>32</sup> Although there is a cost to systems 261 change, the return on investment from tobacco cessation is well established.<sup>33</sup> Additionally, the 262 263 study highlights the necessity of raising awareness among medical providers and their leadership about adopting systems-based solutions to tobacco cessation with attention to documentation and 264 billing. Well-established paradigms for systems change have been developed and evaluated.<sup>34</sup> 265

These include elements of EMR and claims system design, training, and program
evaluation.<sup>35,36,37</sup> Through these actions, it is reasonable to presume improvement in tobacco
cessation interventions, increased revenue for medical practices and reduced burden of tobaccorelated diseases.

270

Our study provides valuable insight to providers measuring the potential impact of applying value-based approaches in population health for tobacco cessation. Ultimately, this research emphasizes the critical need for systemic changes that not only foster financial efficiency but also prioritize and effectively deliver public health interventions. Implementing such changes could lead to a paradigm shift in healthcare delivery, aligning financial incentives with public health goals and elevating the quality of patient care.

277

#### 278 Limitations

279 We acknowledge several limitations of our study. First, while we provide a general framework 280 for providers to measure the impact of undelivered tobacco cessation, our results have limited 281 generalizability to other parts of the country outside the northeast United States as they are from 282 one health system. A second limitation is that the estimated revenue loss is conservative. 283 Tobacco use is not adequately captured in EHRs, and the reimbursement estimate was based on 284 only the three-minute counseling visit (CPT 99406). Given the national prevalence of tobacco use is 18.7%,<sup>1</sup> the reported results of missed opportunities are likely understated. Third, we only 285 286 considered primary care encounters. This means we excluded any other outpatient specialties 287 that might also be offering tobacco cessation counseling. Because we filtered our data by 288 primary care, there may be a greater burden of unrealized potential that we did not measure. The

289 current report is based entirely on EMR indicators of tobacco use and claims data and does not 290 capture the full range of tobacco cessation services such as prescriptions and/or referral to quit 291 lines. Future studies should attempt to capture this type of information to better distinguish 292 between underbilling and opportunities completely missed. Finally, our study is limited by the 293 wide variation in payer reimbursement, even for the same CPT codes, along with the cautious 294 estimates we employed when assessing the three payers. Actual reimbursement varies by region 295 and contract, which should be considered when interpreting our findings. Some contracts with 296 insurers may be based on capitation, and the services may not be specifically reimbursable. 297 However, the return on investment from smoking cessation is well established, and the rate of 298 reimbursement underestimates the future avoided medical expense. 299 Conclusion 300 This study provides evidence of the untapped potential revenue for consistent and systematic 301 tobacco cessation care. The marked discrepancy between eligible and billed cessation services

302 points to either a possible broader trend of underutilizing public health interventions, or a lack of

303 adequate validation in tobacco cessation care delivery. This highlights an opportunity to apply

304 systems-based approaches to tobacco cessation care to improve patient outcomes and economic

305 returns.

Criteria	Details <sup>a</sup>				
EligibleLevel 2-5 Evaluation and Management (E/M) codes, Qualifying CurrentEncounterProcedural Terminology (CPT) or Healthcare Common Procedure Coding SystemCodes(HCPCS) codes					
Tobacco Product Use	Tobacco Use of any tobacco product, including but not limited to cigarettes, cigars,				
Exclusion Patients with limited life expectancy, including those receiving hospice services, Criteria and any patients with medical reasons that justify not screening for tobacco use or not providing tobacco cessation interventions. <sup>b</sup>					
<sup>a</sup> List of CPT/HCPCS Codes   CMS. Accessed February 6, 2024. <u>https://www.cms.gov/medicare/regulations-guidance/physician-self-referral/list-cpt/hcpcs-codes</u> <sup>b</sup> Explore Measures & Activities. Accessed February 6, 2024. <u>https://qpp.cms.gov/mips/explore-measures</u>					
Note: Tobacco cessation intervention can be performed by any healthcare provider, not necessarily the same provider who conducted the tobacco use screening. <sup><math>38</math></sup>					

#### Table 1. Summary of Eligibility Parameters for Tobacco Cessation Care Billing

# 307 Table 2. Patient Demographics by Visit Type, WellSpan Health (January 1, 2021 to December308 31, 2023)

	Office	%	Telemedicine	%	Total Patients <sup>a</sup>	%
Race						
White	444,142	83.4%	67,570	85.3%	487,617	83.4%
Other	36,957	6.9%	5,419	6.8%	40,005	6.8%
Black or African American	25,750	4.8%	3,920	4.9%	27,724	4.7%
Unknown, declined, or not reported	18,301	3.4%	1,394	1.8%	21,115	3.6%
Asian	6,276	1.2%	761	1.0%	7,059	1.2%
American Indian, Alaska Native, Native Hawaiian and Other Pacific Islander	1,018	0.2%	169	0.2%	1,111	0.2%
Ethnicity						
Not Hispanic or Latino	469,761	88.2%	71,716	90.5%	514,657	88.0%
Hispanic or Latino	38,485	7.2%	5,659	7.1%	41,633	7.1%
Unknown, declined, or not reported	24,198	4.5%	1,858	2.3%	28,341	4.8%
Legal sex <sup>b</sup>						
Female	292,413	54.9%	53,592	67.6%	319,039	54.6%
Male	239,943	45.1%	25,619	32.3%	265,498	45.4%
Age <sup>c</sup>						
18-29y	119,222	22.4%	18,305	23.1%	129,076	22.1%
30-44y	141,613	26.6%	29,582	37.3%	153,093	26.2%
45-64y	182,827	34.3%	29,394	37.1%	201,231	34.4%
65+y	140,836	26.5%	13,097	16.5%	157,133	26.9%
Insurance type <sup>d</sup>						
Commercial (Highmark, Blue Cross, etc.)	294,719	55.4%	48,078	60.7%	324,457	55.5%
Medicare	140,399	26.4%	13,900	17.5%	155,162	26.5%
Medicaid	87,684	16.5%	16,457	20.8%	92,285	15.8%
Government/Tricare	9,189	1.7%	1,035	1.3%	10,042	1.7%
Other	64,605	12.1%	3,488	4.4%	125,421	21.5%
Total	532,444	91.1%	79,233	13.6%	584,631	100.0%

<sup>a</sup> Cumulative percentages for visit types exceed 100% as patients may have both an office visit and video visit during the study period.

<sup>b</sup> Percentages are calculated based on tallies of patients' legal sex since these values remain consistent over time

<sup>c</sup> Age values can show discrepancies of approximately 5% between cohorts, primarily because some ages are recorded in months and may not be accurately accounted for in the EMR. Additionally, certain ages can change during the measurement time frame, so cumulative percentages exceed 100%.

<sup>d</sup> SlicerDicer can only measure proportions of encounters associated with the financial payer class, making them unavailable for regression analysis. Separating self-pay data from cost-sharing (co-pays and deductibles) can be challenging, resulting in imprecise measurements, as patients can switch payers within the study period. Notably, this challenge can be exacerbated in the blended group, where patients receive both types of care. In the case of Medicare and Medicaid, there might be overlap among patients with both payer types. The key insight from the payer data is the comparable distribution of percentages across exposure groups.

310	Table 3. Primary Care	e Tobacco Cessation	Counseling by Year
-----	-----------------------	---------------------	--------------------

311

Category	2021 (%)	2022 (%)	2023 (%)	Total (%)	Average (%)
Patients					
Total	405,485	380,204	375,704	584,631	387,131
Persons using tobacco	43,695 (10.8%)	44,285 (11.6%)	42,385 (11.3%)	75,115 (12.8%)	43,455 (11.2%)
Persons using tobacco billed for cessation	622 (1.4%)	545 (1.2%)	218 (0.5%)	1,277 (1.7%)	462 (1.1%)
Visits					
Persons using tobacco, total primary care encounters	169,215	172,688	165,753	507,656	169,219
Persons using tobacco, encounters billed for cessation	731 (0.4%)	596 (0.3%)	230 (0.1%)	1,557 (0.3%)	519 (0.3%)
Encounters with other insurance type or no insurance	11,889	11,067	9,631	32,587	10,862
Non-reimbursable encounters*	24,047	24,508	22,459	71,014	23,671
Unbilled encounters	132,548	136,517	133,433	402,498	134,166

\* This number reflects visits that exceed the maximum reimbursable visits for our 3 payers of interest. For example, Medicare covers up to 8 cessation attempts per year, so Medicare patients with more than 8 visits in a year will only count as having 8 eligible visits.

## 312

# 313 Table 4: Estimated Reimbursement Based on Payer Type

314

Payer	2021 Eligible Visits (est. reimbursement)	2022 Eligible Visits (est. reimbursement)	2023 Eligible Visits (est. reimbursement)	Total Eligible Visits (est. reimbursement)	Avg. Eligible Visits (est. reimbursement)
Commercial	35,864	36,359	35,471	107,694	35,898
\$20.96	(\$751,637.71)	(\$762,011.92)	(\$743,401.22)	(\$2,257,050.85)	(\$752,350.28)
Medicare	41,986	44,995	46,779	133,760	44,587
\$14.97	(\$628,530.42)	(\$673,575.15)	(\$700,281.63)	(\$2,002,387.20)	(\$667,462.40)
Medicaid	54,698	55,163	51,183	161,044	53,681
\$10.48	(\$573,180.34)	(\$578,053.08)	(\$536,346.66)	(\$1,687,580.08)	(\$562,526.69)
Total	132,548 (\$1,953,348.47)	136,517 (\$2,013,640.15)	133,433 (\$1,980,029.51)	402,498 (\$5,947,018.13)	134,166 (\$1,982,339.38)

#### 316 References

<sup>1</sup> Cornelius ME, Loretan CG, Jamal A, et al. Tobacco Product Use Among Adults - United States, 2021. *MMWR Morb Mortal Wkly Rep.* May 5 2023;72(18):475-483. doi:10.15585/mmwr.mm7218a1

<sup>2</sup> Smoking Cessation: A Report of the Surgeon General. 2020. Publications and Reports of the Surgeon General.

<sup>3</sup> New reference required Babb, S., et al. (2017). "Quitting smoking among adults—United States, 2000–2015." <u>Morbidity and Mortality Weekly Report</u> **65**(52): 1457-1464.

<sup>4</sup> NCQA. Medical Assistance with Smoking and Tobacco Use Cessation. Accessed 5/15/2023, 2023. https://www.ncqa.org/hedis/measures/medical-assistance-with-smoking-and-tobacco-use-cessation/

<sup>5</sup> Malloy, K., Proj, A., Battles, H., Juster, T., Ortega-Peluso, C., Wu, M., & Juster, H. (2018). Smoking cessation benefit utilization: comparing methodologies for measurement using New York State's Medicaid data. *Nicotine and Tobacco Research*, *20*(12), 1467-1473.)

<sup>6</sup> Tibuakuu, M., Okunrintemi, V., Jirru, E., Tcheugui, J. B. E., Orimoloye, O. A., Mehta, P. K., ... & Michos, E. D. (2019). National trends in cessation counseling, prescription medication use, and associated costs among US adult cigarette smokers. *JAMA network open*, 2(5), e194585-e194585.

<sup>7</sup> Sardana M, Tang Y, Magnani JW, et al. Provider-Level Variation in Smoking Cessation Assistance Provided in the Cardiology Clinics: Insights From the NCDR PINNACLE Registry. *J Am Heart Assoc*. Jul 2 2019;8(13):e011412. doi:10.1161/JAHA.118.011307

<sup>8</sup> Hoel AW, Nolan BW, Goodney PP, et al. Variation in smoking cessation after vascular operations. *J Vasc Surg*. May 2013;57(5):1338-44; quiz 1344 e1-4. doi:10.1016/j.jvs.2012.10.130

<sup>9</sup> Goldstein MG, DePue JD, Monroe AD, et al. A population-based survey of physician smoking cessation counseling practices. *Prev Med.* Sep-Oct 1998;27(5 Pt 1):720-9. doi:10.1006/pmed.1998.0350

<sup>10</sup> Wang X, Babb S, Xu X, Ku L, Glover-Kudon R, Armour BS. Receipt of cessation treatments among Medicaid enrollees trying to quit smoking. *Nicotine and Tobacco Research*. 2021;23(6):1074-1078.

<sup>11</sup> Huerne, K., & Eisenberg, M. J. (2023). Vaping Cessation Interventions in Former Smokers: A Review. *Canadian Journal of Cardiology*.

<sup>12</sup> Patnode CD, Henderson JT, Coppola EL, Melnikow J, Durbin S, Thomas RG. Interventions for Tobacco Cessation in Adults, Including Pregnant Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA*. 2021;325(3):280–298. doi:10.1001/jama.2020.23541

<sup>13</sup> Michael C. Fiore, Douglas E. Jorenby, Timothy B. Baker, Smoking cessation: Principles and practice based upon the AHCPR Guideline, 1996, *Annals of Behavioral Medicine*, Volume 19, Issue 3, September 1997, Pages 213–219, <u>https://doi.org/10.1007/BF02892286</u>

<sup>14</sup> United States Public Health Service Office of the Surgeon General; National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. *Smoking Cessation: A Report of the Surgeon General*. Washington (DC): US Department of Health and Human Services; 2020.

<sup>15</sup> Malloy, K., Proj, A., Battles, H., Juster, T., Ortega-Peluso, C., Wu, M., & Juster, H. (2018). Smoking cessation benefit utilization: comparing methodologies for measurement using New York State's Medicaid data. *Nicotine and Tobacco Research*, *20*(12), 1467-1473.

<sup>16</sup> Patel, N., Miller Jr, D. P., Snavely, A. C., Bellinger, C., Foley, K. L., Case, D., ... & Dharod, A. (2020). A comparison of smoking history in the electronic health record with self-report. *American journal of preventive medicine*, *58*(4), 591-595.

<sup>17</sup> McCullough JM. Timing of Clinical Billing Reimbursement for a Local Health Department. *Public Health Rep.* 2016;131(2):283-289. doi:10.1177/003335491613100212

<sup>18</sup> Tobacco, T. C. P. G. T. (2008). A clinical practice guideline for treating tobacco use and dependence: 2008 update: a US public health service report. *American journal of preventive medicine*, *35*(2), 158-176.)

<sup>19</sup> PA Department of Health. Pennsylvania Tobacco Data. Department of Health. Accessed December 8, 2023. https://www.health.pa.gov:443/topics/programs/tobacco/Pages/Data.aspx

<sup>20</sup> Billing Guide for Tobacco Screening and Cessation. https://www.lung.org/getmedia/08ed3536-6bab-48a6-a4e4-e6dbccaea024/billing-guide-for-tobacco-1.pdf.pdf

<sup>21</sup> Centers for Medicare & Medicaid Services. Accessed January 1, 2024. https://www.cms.gov/medicare/physician-fee-

schedule/search?Y=0&T=4&HT=1&CT=0&H1=99406&H2=99407&M=5

<sup>22</sup> Explanation of data standards for race, ethnicity, sex, primary language, and disability. Office of Minority Health. Accessed December 12, 2023. https://minorityhealth.hhs.gov/explanation-data-standards-race-ethnicity-sex-primary-language-and-disability.

<sup>23</sup> Cornelius, M. E., Wang, T. W., Jamal, A., Loretan, C. G., Willis, G., Graham-Glover, B., & Neff, L. (2023). Peer Reviewed: State-Specific Prevalence of Adult Tobacco Product Use and Cigarette Smoking Cessation Behaviors, United States, 2018–2019. *Preventing Chronic Disease*, 20.

<sup>24</sup> McCarthy DE, Baker TB, Zehner ME, et al. A comprehensive electronic health record-enabled smoking treatment program: Evaluating reach and effectiveness in primary care in a multiple baseline design. *Prev Med.* 2022;165(Pt B):107101. doi:10.1016/j.ypmed.2022.107101

<sup>25</sup> Medical Assistance with Smoking and Tobacco Use Cessation. NCQA. Accessed January 16, 2024. <u>https://www.ncqa.org/hedis/measures/medical-assistance-with-smoking-and-tobacco-use-cessation/</u>

<sup>26</sup> Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T. Physician advice for smoking cessation. *Cochrane Database Syst Rev.* 2013;2013(5):CD000165. Published 2013 May 31. doi:10.1002/14651858.CD000165.pub4

<sup>27</sup> Adams JM. Smoking Cessation—Progress, Barriers, and New Opportunities: The Surgeon General's Report on Smoking Cessation. *JAMA*. 2020;323(24):2470–2471. doi:10.1001/jama.2020.6647

<sup>28</sup> Pipe AL, Evans W, Papadakis S. Smoking cessation: health system challenges and opportunities. *Tob Control*. 2022;31(2):340-347. doi:10.1136/tobaccocontrol-2021-056575

<sup>29</sup> Berlin, I. (2008). Physicians' perceived barriers to promoting smoking cessation. *Journal of Smoking Cessation*, *3*(2), 92-100.

<sup>30</sup> Kushnir V, Cunningham JA. Assessing effective smoking cessation intervention in primary care. *Preventive Medicine Reports*. 2015;2:181-182. doi:<u>10.1016/j.pmedr.2015.03.001</u>

<sup>31</sup> Schaer DA, Singh B, Steinberg MB, Delnevo CD. Tobacco Treatment Guideline Use and Predictors Among U.S. Physicians by Specialty. *American Journal of Preventive Medicine*. 2021;61(6):882-889. doi:10.1016/j.amepre.2021.05.014

<sup>32</sup> Kilanko V. The Transformative Potential of Artificial Intelligence in Medical Billing: A Global Perspective. 2023;4(3). doi:https://doi.org/10.51542/ijscia.v4i3.8

<sup>33</sup> Warner, K. E. (1997). Cost effectiveness of smoking-cessation therapies: interpretation of the evidence and implications for coverage. *Pharmacoeconomics*, *11*(6), 538-549.

<sup>34</sup> Systems Change: Treating Tobacco Use and Dependence. Content last reviewed December 2012. Agency for Healthcare Research and Quality, Rockville, MD.

https://www.ahrq.gov/prevention/guidelines/tobacco/decisionmakers/systems/index.html

<sup>35</sup> Burks K, Shields J, Evans J, Plumley J, Gerlach J, Flesher S. A systematic review of outpatient billing practices. *SAGE Open Medicine*. 2022;10:205031212210990. doi:https://doi.org/10.1177/20503121221099021

<sup>36</sup> Wright JS, Wall HK, Ritchey MD. Million Hearts 2022: small steps are needed for cardiovascular disease prevention. JAMA. 2018;320(18):1857-1858.

<sup>37</sup> American Academy of Family Physicians. Office Champions: A Systems Change Approach. Accessed May 5, 2024. <u>https://www.aafp.org/family-physician/patient-care/care-resources/tobacco-and-nicotine/office-champions.html</u>

<sup>38</sup> Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention | eCQI Resource Center. Accessed December 8, 2023. <u>https://ecqi.healthit.gov/ecqm/ec/2021/cms138v9#</u>